Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30621106 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL31121260 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL30915198 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL29702364 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL19725977 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL2607961 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL12107853 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL17256399 | 0.97 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL18084278 | 0.96 | HPGD (0.44) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL14701730 | 0.91 | HPGD (0.41) | HPGDSMN1; SMN2NPC1RAB9ADDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130041133-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041133-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | PHAX, NSUN3, NSUN2 | HPGD 4632/4885SMN1; SMN2 575/4885NPC1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.